Evidence mapPaperPMID 39830909Full record

ReviewFood science & nutrition2025

Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies.

Mahwish, Muhammad Imran, Hammad Naeem, Muzzamal Hussain, Suliman A Alsagaby, Waleed Al Abdulmonem, Ahmed Mujtaba, Mohamed A Abdelgawad, Mohammed M Ghoneim, Ahmed H El-Ghorab and 4 more

Abstract readReview
In one paragraph

Review in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Luteolin alleviates inflammation by inhibiting the PI3K-Akt-FOXO3a pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Crystal structure and Hirshfeld surface analysis of luteolin dimethyl sulfoxide monosolvate.Acta crystallographica. Section E, Crystallographic communications · 2026
    Article
  8. Review
  9. Preliminary Studies on In Vitro Antibacterial Activity AgainstPharmaceuticals (Basel, Switzerland) · 2026
    Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Pharmaceuticals (Basel, Switzerland) · 2025
    Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

MahwishInstitute of Food Science and Nutrition University of Sargodha Sargodha Pakistan.ORCID https://orcid.org/0000-0002-7931-0778
Muhammad ImranDepartment of Food Science and Technology University of Narowal Narowal Pakistan.
Hammad NaeemDepartment of Food Science and Technology Muhammad Nawaz Shareef University of Agriculture Multan Pakistan.
Muzzamal HussainDepartment of Food Sciences Government College University Faisalabad Faisalabad Pakistan.ORCID https://orcid.org/0000-0001-6508-1962
Suliman A AlsagabyDepartment of Medical Laboratory Sciences, College of Applied Medical Sciences Majmaah University AL-Majmaah Saudi Arabia.
Waleed Al AbdulmonemDepartment of Pathology, College of Medicine Qassim University Buraidah Saudi Arabia.
Ahmed MujtabaDepartment of Food Sciences and Technology, Faculty of Engineering and Technology Hamdard University Islamabad campus Islamabad Pakistan.
Mohamed A AbdelgawadDepartment of Pharmaceutical Chemistry, College of Pharmacy Jouf University Aljouf Saudi Arabia.
Mohammed M GhoneimDepartment of Pharmacy Practice, College of Pharmacy AlMaarefa University Riyadh Saudi Arabia.
Ahmed H El-GhorabDepartment of Chemistry, College of Science Jouf University Sakaka Saudi Arabia.
Samy SelimDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences Jouf University Sakaka Saudi Arabia.ORCID https://orcid.org/0000-0003-4025-8586
Soad K Al JaouniDepartment of Hematology/Oncology, Yousef Abdulatif Jameel Scientific Chair of Prophetic Medicine Application, Faculty of Medicine King Abdulaziz University Jeddah Saudi Arabia.
Ehab M MostafaDepartment of Pharmacognosy, College of Pharmacy Jouf University Sakaka Saudi Arabia.
Tadesse Fenta YehualaFaculty of Chemical and Food Engineering, Bahir Dar Institute of Technology Bahir Dar University Bahir Dar Ethiopia.ORCID https://orcid.org/0000-0001-9241-0266

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Luteolin is widely distributed phytochemical, a flavonoid, in kingdom plantae. Luteolin with potential antioxidant activity prevent ROS-induced damages and reduce oxidative stress which is mainly responsible in pathogenesis of many diseases. Several chemo preventive activities and therapeutic benefits are associated with luteolin. Luteolin prevents cancer via modulation of numerous pathways, that is, by inactivating proteins; such as procaspase-9, CDC2 and cyclin B or upregulation of caspase-9 and caspase-3, cytochrome C, cyclin A, CDK2, and APAF-1, in turn inducing cell cycle arrest as well as apoptosis. It also enhances phosphorylation of p53 and expression level of p53-targeted downstream gene. By Increasing BAX protein expression; decreasing VEGF and Bcl-2 expression it can initiate cell cycle arrest and apoptosis. Luteolin can stimulate mitochondrial-modulated functions to cause cellular death. It can also reduce expression levels of p-Akt, p-EGFR, p-Erk1/2, and p-STAT3. Luteolin plays positive role against cardiovascular disorders by improving cardiac function, decreasing the release of inflammatory cytokines and cardiac enzymes, prevention of cardiac fibrosis and hypertrophy; enhances level of CTGF, TGFβ1, ANP, Nox2, Nox4 gene expressions. Meanwhile suppresses TGFβ1 expression and phosphorylation of JNK. Luteolin helps fight diabetes via inhibition of alpha-glucosidase and ChE activity. It can reduce activity levels of catalase, superoxide dismutase, and GS4. It can improve blood glucose, insulin, HOMA-IR, and HbA1c levels. This review is an attempt to elaborate molecular targets of luteolin and its role in modulating irregularities in cellular pathways to overcome severe outcomes during diseases including cancer, cardiovascular disorders, diabetes, obesity, inflammation, Alzheimer's disease, Parkinson's disease, hepatic disorders, renal disorders, brain injury, and asthma. As luteolin has enormous therapeutic benefits, it could be a potential candidate in future drug development strategies.

Indexed as

anticancerantidiabeticanti‐inflammatoryantioxidantflavonoidluteolinphytochemical

Identifiers

PMID39830909
PMCPMC11742186

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.